Francesco Russo1, Guglielmina Chimienti2, Caterina Clemente3, Carla Ferreri4, Antonella Orlando3, Giuseppe Riezzo3. 1. Laboratory of Nutritional Pathophysiology, National Institute for Digestive Diseases I.R.C.C.S. "Saverio de Bellis", Via Turi 27, 70013, Castellana Grotte, Bari, Italy. francesco.russo@irccsdebellis.it. 2. Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy. 3. Laboratory of Nutritional Pathophysiology, National Institute for Digestive Diseases I.R.C.C.S. "Saverio de Bellis", Via Turi 27, 70013, Castellana Grotte, Bari, Italy. 4. Consiglio Nazionale delle Ricerche (CNR), ISOF Bio Free Radicals, Bologna, Italy.
Abstract
PURPOSE: A gluten-free diet (GFD) has been reported to negatively impact the quality of life (QoL) of coeliac disease (CD) patients. The gut-brain axis hormones ghrelin and leptin, with the brain-derived neurotrophic factor (BDNF), may affect QoL of CD patients undergoing GFD. Our aims were to evaluate whether: (a) the circulating concentrations of leptin, ghrelin and BDNF in CD patients were different from those in healthy subjects; (b) GFD might induce changes in their levels; (c) BDNF Val66Met polymorphism variability might affect BDNF levels; and (d) serum BDNF levels were related to dietary docosahexaenoic acid (DHA) as a neurotrophin modulator. METHODS: Nineteen adult coeliac patients and 21 healthy controls were included. A QoL questionnaire was administered, and serum concentrations of ghrelin, leptin, BDNF and red blood cell membrane DHA levels were determined at the enrolment and after 1 year of GFD. BDNF Val66Met polymorphism was analysed. RESULTS: Results from the questionnaire indicated a decline in QoL after GFD. Ghrelin and leptin levels were not significantly different between groups. BDNF levels were significantly (p = 0.0213) lower in patients after GFD (22.0 ± 2.4 ng/ml) compared to controls (31.2 ± 2.2 ng/ml) and patients at diagnosis (25.0 ± 2.5 ng/ml). BDNF levels correlated with DHA levels (p = 0.008, r = 0.341) and the questionnaire total score (p = 0.041, r = 0.334). CONCLUSIONS: Ghrelin and leptin seem to not be associated with changes in QoL of patients undergoing dietetic treatment. In contrast, a link between BDNF reduction and the vulnerability of CD patients to psychological distress could be proposed, with DHA representing a possible intermediate.
PURPOSE: A gluten-free diet (GFD) has been reported to negatively impact the quality of life (QoL) of coeliac disease (CD) patients. The gut-brain axis hormones ghrelin and leptin, with the brain-derived neurotrophic factor (BDNF), may affect QoL of CDpatients undergoing GFD. Our aims were to evaluate whether: (a) the circulating concentrations of leptin, ghrelin and BDNF in CDpatients were different from those in healthy subjects; (b) GFD might induce changes in their levels; (c) BDNF Val66Met polymorphism variability might affect BDNF levels; and (d) serum BDNF levels were related to dietary docosahexaenoic acid (DHA) as a neurotrophin modulator. METHODS: Nineteen adult coeliac patients and 21 healthy controls were included. A QoL questionnaire was administered, and serum concentrations of ghrelin, leptin, BDNF and red blood cell membrane DHA levels were determined at the enrolment and after 1 year of GFD. BDNF Val66Met polymorphism was analysed. RESULTS: Results from the questionnaire indicated a decline in QoL after GFD. Ghrelin and leptin levels were not significantly different between groups. BDNF levels were significantly (p = 0.0213) lower in patients after GFD (22.0 ± 2.4 ng/ml) compared to controls (31.2 ± 2.2 ng/ml) and patients at diagnosis (25.0 ± 2.5 ng/ml). BDNF levels correlated with DHA levels (p = 0.008, r = 0.341) and the questionnaire total score (p = 0.041, r = 0.334). CONCLUSIONS:Ghrelin and leptin seem to not be associated with changes in QoL of patients undergoing dietetic treatment. In contrast, a link between BDNF reduction and the vulnerability of CDpatients to psychological distress could be proposed, with DHA representing a possible intermediate.
Authors: Sarah J Spencer; Lu Xu; Melanie A Clarke; Moyra Lemus; Alex Reichenbach; Bram Geenen; Tamás Kozicz; Zane B Andrews Journal: Biol Psychiatry Date: 2012-04-21 Impact factor: 13.382
Authors: Nathalie J M van Hees; Erik J Giltay; Johanna M Geleijnse; Nadine Janssen; Willem van der Does Journal: PLoS One Date: 2014-05-19 Impact factor: 3.240
Authors: Jonas F Ludvigsson; Carolina Ciacci; Peter Hr Green; Katri Kaukinen; Ilma R Korponay-Szabo; Kalle Kurppa; Joseph A Murray; Knut Erik Aslaksen Lundin; Markku J Maki; Alina Popp; Norelle R Reilly; Alfonso Rodriguez-Herrera; David S Sanders; Detlef Schuppan; Sarah Sleet; Juha Taavela; Kristin Voorhees; Marjorie M Walker; Daniel A Leffler Journal: Gut Date: 2018-02-13 Impact factor: 23.059
Authors: Maria Grunewald; Christian Hellmuth; Franca F Kirchberg; Maria Luisa Mearin; Renata Auricchio; Gemma Castillejo; Ilma R Korponay-Szabo; Isabel Polanco; Maria Roca; Sabine L Vriezinga; Katharina Werkstetter; Berthold Koletzko; Hans Demmelmair Journal: Nutrients Date: 2019-08-30 Impact factor: 5.717